Abstract
BackgroundBempedoic acid and Ezetimibe acid are used in combination for treatment of hypercholesterolemia. The current work was undertaken to develop a simple and rapid stability-indicating RP-UPLC method for the simultaneous estimation of Bempedoic acid and Ezetimibe in tablets as no such method was available. The chromatographic separation was performed with Waters Acquity C18 [50 × 2.1 mm, 1.7 μ] column using methanol: acetonitrile: water [50: 30: 20, by volume] as mobile phase pumped at a flow rate 0.5 mL/min. The separated analytes were detected at 260 nm using UV detector.ResultsThe separation of Bempedoic acid (BA) and Ezetimibe (EZ) was done at a retention time of 1.827 min. and 3.577 min. respectively. The validation and stability studies of the present method were carried out according to the ICH guidelines. The linearity of the proposed method was in the range of 30–130 μg/mL and 5–50 μg/mL for Bempedoic acid and Ezetimibe respectively. Limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.1216 μg/mL and 0.3685 μg/mL for Bempedoic acid and 0.1189 μg/mL and 0.3602 μg/mL for Ezetimibe respectively. The recovery of the method was found to be in the range of 99.89—100.31% for Bempedoic acid and 98.14—99.94% for Ezetimibe while the % RSD for both drugs in the precision and robustness study was less than 2.0. The drugs did not show any major degradants in the exposed conditions.ConclusionThe developed method was found to be simple, sensitive, accurate, precise, robust, rapid and yet stability indicating. The method can be adopted for simultaneous estimation of Bempedoic acid and Ezetimibe in the pharmaceutical formulation.
Highlights
Bempedoic acid and Ezetimibe acid are used in combination for treatment of hypercholesterolemia
High LDL cholesterol (LDL-C) levels represent an important risk factor for cardiovascular diseases, which can be due to genetic mutations or lifestyle factors, hypercholesterolemia can substantially reduce life quality and increase the risk of cardiovascular disease mortality
Bempedoic acid (Fig. 1a) and Ezetimibe (Fig. 1b) acid are used in combination for treatment of hypercholesterolemia and Atherosclerotic cardiovascular disease (ASCVD) by reducing lipid parameters and attenuating hsCRP levels [1]
Summary
Bempedoic acid and Ezetimibe acid are used in combination for treatment of hypercholesterolemia. Bempedoic acid (Fig. 1a) and Ezetimibe (Fig. 1b) acid are used in combination for treatment of hypercholesterolemia and ASCVD by reducing lipid parameters and attenuating hsCRP levels [1]. Ezetimibe is an azetidinone derivative, it prevents absorption of cholesterol by blocking the Niemann-Pick C1-like 1 (NPC1L1) protein on epithelial cells of gastrointestinal tract, and in hepatocytes. It blocks aminopeptidase N and interfere with caveolin 1-annexin A2 complex which is in cholesterol trafficking.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
